On May 6th, an investor asked a question to Shunho shares (003565) on the interactive platform, "It is rumored that the company's shareholding company Yunnan Xike has been granted authorization for the patent 'Synthetic Nicotine Composition' in the United States. This patented technology will be used to expand into the biopharmaceutical sector. Can you confirm this? Does the company or its subsidiaries have any other strategic plans in the field of synthetic biology?
Shunho Corporation stated that its affiliated company, Yunnan Xike Technology Co., Ltd., was granted the invention patent "Synthetic Nicotine Composition" in August 2021, and this patent is still valid. The synthetic nicotine composition covered by this patent technology has the advantages of safety, stability, and ease of storage. It can be used in various fields such as low-temperature HNB products, e-cigarettes, nicotine release patches, pharmaceutical synthesis, etc.
We welcome news tips, article submissions, interview requests, or comments on this piece.
Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn
Notice
1. This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.
2. The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.
3. This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.
4. Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.
Copyright
This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.
For copyright-related inquiries, please contact: info@2firsts.com
AI Assistance Disclaimer
This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.
We welcome any corrections or feedback. Please contact us at: info@2firsts.com
